Tuesday, November 15, 2022 Daily Archives

Intensified Biomanufacturing: Achieving 3-4-Fold Higher Titers of mAbs Using Syngene’s Intensified Fed-Batch Process

Mammalian cell lines are predominantly used to produce mAbs. The current commercial production method uses fed-batch processes that exhibit productivity titers from 1- 5 g/L. Productivity is measured by the volume of products made in each batch. In the fed-batch process, the media and/or feeds are constantly supplied to the bioreactor during the cultivation, where the desired cells produce the product of interest. Productivity variation arises depending on the nature of the antibody and the specific cell line used. Higher…

WuXi Vaccines buys Harbour BioMed China facility

The manufacturing facility in Suzhou, China will support vaccine development and production for its global partners, says WuXi Vaccines. Contract development and manufacturing organization (CDMO) WuXi Vaccines says the facility acquired from Harbour BioMed will be its first standalone vaccine development and production plant located in China. “Safe and effective vaccines play an increasingly important role in preventive healthcare,” Jian Dong, CEO of WuXi Vaccines told us. “There is increasing demand for vaccines CDMO services from our global clients as…